Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Xenon Pharmaceuticals Inc (NASDAQ: XENE) was $30.64 for the day, down -8.67% from the previous closing price of $33.55. In other words, the price has decreased by -$8.67 from its previous closing price. On the day, 1.12 million shares were traded. XENE stock price reached its highest trading level at $33.64 during the session, while it also had its lowest trading level at $30.58.
Ratios:
Our analysis of XENE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 17.85 and its Current Ratio is at 17.85. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on February 11, 2025, initiated with a Buy rating and assigned the stock a target price of $67.
On October 01, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $53.H.C. Wainwright initiated its Buy rating on October 01, 2024, with a $53 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 24 ’25 when MORTIMER IAN sold 22,468 shares for $40.20 per share. The transaction valued at 903,214 led to the insider holds 31,302 shares of the business.
MORTIMER IAN sold 16,315 shares of XENE for $660,806 on Jan 27 ’25. The PRESIDENT & CEO now owns 31,302 shares after completing the transaction at $40.50 per share. On Jan 23 ’25, another insider, MORTIMER IAN, who serves as the PRESIDENT & CEO of the company, sold 16,217 shares for $40.08 each. As a result, the insider received 649,977 and left with 31,302 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XENE now has a Market Capitalization of 2345271296 and an Enterprise Value of 1727381760.
Stock Price History:
The Beta on a monthly basis for XENE is 1.22, which has changed by -0.25811136 over the last 52 weeks, in comparison to a change of 0.08089435 over the same period for the S&P500. Over the past 52 weeks, XENE has reached a high of $46.00, while it has fallen to a 52-week low of $32.70. The 50-Day Moving Average of the stock is -18.19%, while the 200-Day Moving Average is calculated to be -22.87%.
Shares Statistics:
XENE traded an average of 449.29K shares per day over the past three months and 470450 shares per day over the past ten days. A total of 76.42M shares are outstanding, with a floating share count of 74.20M. Insiders hold about 3.05% of the company’s shares, while institutions hold 97.30% stake in the company. Shares short for XENE as of 1741910400 were 3641348 with a Short Ratio of 8.10, compared to 1739491200 on 3922057. Therefore, it implies a Short% of Shares Outstanding of 3641348 and a Short% of Float of 4.79.
